- ISIN
- US10501L1061
- CUSIP
- 10501L106
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Oct 6, 1999
Highlights
- Market Cap
- $597.37M
- Enterprise Value
- $545.44M
- EPS (TTM)
- $0.34
- PE Ratio
- 44.95
- PEG Ratio
- 0.12
- Total Revenue (TTM)
- $56.22M
- Gross Profit (TTM)
- $42.45M
- EBITDA (TTM)
- $12.57M
- Year Range
- $5.70 - $17.35
- Target Price
- $15.00
- ROA (TTM)
- 7.54%
- ROE (TTM)
- 11.63%
- Avg. Volume (1M)
- 135K
- Avg. Volume Value (1M)
- $2.10M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BWAY Performance Chart
BrainsWay Ltd. (BWAY) is up 60.2% since the beginning of the year. At $15 per share, BWAY is trading 12.2% below its 52-week high of $17. Investors who bought $1,000 worth of BWAY shares 5 years ago would now be looking at an investment worth $3,400.
Loading charts...
Compare this symbol against anything
Returns By Period
BrainsWay Ltd. (BWAY) has returned 60.15% so far this year and 165.56% over the past 12 months.
BrainsWay Ltd.
- 1D
- -0.13%
- 1M
- 0.26%
- 6M
- 30.28%
- YTD
- 60.15%
- 1Y
- 165.56%
- 3Y*
- 135.57%
- 5Y*
- 27.73%
- 10Y*
- —
- ALL TIME*
- 14.81%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
BWAY Monthly Returns History
Based on dividend-adjusted daily data since Apr 17, 2019, BWAY's average daily return is +0.13%, while the average monthly return is +2.60%. At this rate, an investment would double in approximately 2.3 years.
Historically, 50% of months were positive and 50% were negative. The best month was Nov 2023 with a return of +75.6%, while the worst month was Nov 2022 at -46.0%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.
On a daily basis, BWAY closed higher 47% of trading days. The best single day was Jan 21, 2021 with a return of +22.2%, while the worst single day was Nov 16, 2022 at -31.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 22.92% | -1.03% | 14.87% | 24.60% | -4.05% | -2.39% | -1.81% | 60.15% | |||||
| 2025 | 11.45% | -9.13% | -0.84% | -8.45% | 17.65% | 28.92% | -11.18% | 33.22% | -3.15% | 11.81% | 3.80% | 8.75% | 101.70% |
| 2024 | -3.40% | 3.51% | -18.36% | -0.76% | 19.81% | -3.50% | 19.28% | 9.25% | 16.81% | 8.23% | -1.30% | -4.46% | 45.52% |
| 2023 | -18.62% | -3.48% | -9.54% | -11.68% | 13.23% | 29.91% | 6.58% | 41.98% | 17.10% | -11.63% | 75.63% | 3.35% | 162.35% |
| 2022 | 0.65% | 0.32% | 12.28% | -12.14% | -6.78% | -32.45% | 27.33% | -30.98% | -14.96% | -2.77% | -46.01% | 30.34% | -67.92% |
| 2021 | 5.44% | 7.55% | 5.61% | -4.54% | 29.23% | -8.44% | -12.16% | -11.38% | 1.51% | 1.49% | -5.01% | -0.90% | 2.12% |
Benchmark Metrics
BrainsWay Ltd. has an annualized alpha of 20.84%, beta of 0.92, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since April 17, 2019.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (88.44%) than losses (82.51%) - typical of diversified or defensive assets.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 20.84%
- Beta
- 0.92
- R²
- 0.09
- Upside Capture
- 88.44%
- Downside Capture
- 82.51%
Return for Risk
Risk / Return Rank
BWAY ranks 96 for risk / return — above 96% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for BrainsWay Ltd. (BWAY) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BWAY | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.58 | ||
| Sortino ratioReturn per unit of downside risk | +1.54 | ||
| Omega ratioGain probability vs. loss probability | 1.42 | 1.25 | +0.17 |
| Calmar ratioReturn relative to maximum drawdown | 8.47 | 2.00 | +6.47 |
| Martin ratioReturn relative to average drawdown | 19.80 | 8.49 | +11.30 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the BrainsWay Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BrainsWay Ltd. was 88.14%, occurring on May 10, 2023. Recovery took 532 trading sessions.
The current BrainsWay Ltd. drawdown is 11.30%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-88.14%May 2023 | 3y 3mo | 2y 1mo | 5y 5moJan 2020 - Jun 2025 | — |
-27.83%Nov 2019 | 6mo 29d | 1mo 29d | 8mo 28dApr 2019 - Jan 2020 | — |
-19.10%Jun 2026 | 25d | — | 2mo 23dMay 2026 - now | — |
-18.27%Feb 2026 | 8d | 13d | 21dJan 2026 - Feb 2026 | — |
-16.57%Nov 2025 | 16d | 8d | 24dNov 2025 - Nov 2025 | — |
Drawdown Indicators
| BWAY | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -88.14% | -56.78% | -31.36% |
Max Drawdown (1Y)Largest decline over 1 year | -19.10% | -9.10% | -10.00% |
Max Drawdown (3Y)Largest decline over 3 years | -36.33% | -18.90% | -17.43% |
Max Drawdown (5Y)Largest decline over 5 years | -83.71% | -25.43% | -58.28% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -11.30% | -1.58% | -9.72% |
Average DrawdownAverage peak-to-trough decline | -36.57% | -10.70% | -25.87% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.16% | 2.14% | +6.02% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BrainsWay Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BrainsWay Ltd. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for BWAY, comparing it with other companies in the Medical Devices industry. Currently, BWAY has a P/E ratio of 44.9. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for BWAY compared to other companies in the Medical Devices industry. BWAY currently has a PEG ratio of 0.1. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BWAY relative to other companies in the Medical Devices industry. Currently, BWAY has a P/S ratio of 7.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BWAY in comparison with other companies in the Medical Devices industry. Currently, BWAY has a P/B value of 3.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BWAY
Add BrainsWay Ltd. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BWAY